A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Cabozantinib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms COSMIC-312
- Sponsors Exelixis
- 26 Sep 2019 According to an Ipsen media release, an overview of the trial design will be presented at the European Society for Medical Oncology (ESMO) Congress 2019.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2019 Planned number of patients changed from 640 to 740.